DGKA and hepatocellular carcinoma: Indeed, this compound not only induced the apoptosis of HepG2 hepatocellular carcinoma and HeLa cervical cancer cells as observed for other DGK inhibitors with lower-selectivity (Dominguez et al., 2013), but also enhanced the production of interleukin-2 in Jurkat T cells (Liu et al., 2016), illustrating a double-strike effect of DGKα inhibitors potentially utilized for cancer immunotherapy (Noessner, 2017).